1[1]WASID Investigators. Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group. Stroke, 1998, 29: 1389-1392.
2[2]Piotin M , Spelle L, Martin JB, et al. Percutaneous transluminal angioplasty and stenting of the proximal vertebral artery for symptomatic stenosis. Am J Neuroradiol, 2000,21: 727-731.
4[4]Albuquerque FC, Fiorella D, Han P, et al. A reappraisal of angioplasty and stenting for the treatment of vertebral origin stenosis. Neurosurgery. 2003, 53: 607-614.
5[5]Hoffman R , Mintz GS , Dussaillant GR , et al. Patterns and mechanisms of in-stent restenosis: serial intravascular ultrasound study. Circulation, 1996, 94: 1247-1254.
6[6]Carter A J, Kopia G, Llanos G, et al . Stent based sirolimus delivery reduces neointimal proliferation in a porcine coronary model of restenosis. J Am Coll Cardiol, 2000,35: 13.
7[7]Klugherz BD, Llanos G, Lieuallen W, et al. Stent-based delivery of sirolimus for the prevention of restenosis. J Am Coll Cardiol, 2000, 35: 58.
8[8]Degertekin M, Serruys PW, Foley DP, et al. Persistant inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intracascular ultrasound follow-up. Circulation, 2002, 106: 1610-1613.
9[9]Morice MC, Serruys PW, Sousa JE , et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med, 2002, 346:1773-1780.
10[10]Levy EI, Hanel RA, Howington JU, et al. Sirolimus-eluting stents in the canine cerebral vasculature: a prospective, randomized, blinded assessment of safety and vessel response. J Neurosurg. 2004 , 100: 688-694.
二级参考文献4
1[1]Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. The REVEL trial. N Engl J Med, 2002, 346: 1773-1780.
2[2]Patrick W, Muzaffer D, Kengo T, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL trial. Circulation, 2002, 106:798-803.
3[3]Gallo R, Padurean A, Chesebro JH, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries byrapamycin. Circulation, 1998, 99:2164-2170.
4[4]Steven O, Andrew R. The development of rapamycin and its application to stent restenosis. Circulation, 2001, 104:852-855.
6Millikan CH, Siekert RG, Shick RM. Prognosis of patients with symptomatic vertebral or basilar artery stenosis. Stroke, 1998,29: 1389-1392.
7Sundt TM Jr,Smith He, Campbell JK, et al. Transluminal angioplasty for basilar artery stenosis. Mayo Clin Proc, 1980,55:673-680.
8Higashida RT, Tsai FY, Halbach VV, et al. Transluminal angioplasty for atherosclerotic disease of the vertebral and basilar arteries. Neurosurg, 1993,78 : 192-198.
9Estes JM, Guadagnoli E, Wolf R, et al. Beneficial effect of carotid endarterectomy in symptomatic patients with high-gade carotid stcnosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med,1991,325 :445..453.
10Malek AM , Higashida RT , Phatouros CC , et al . Treatment of posterior circulation ischemia with extracranial percutaneous balloon angioplasty and stent placement. Stroke , 1999,30:2073-2085.
